After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination ...
After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination ...
This financial performance reflects the company's robust growth in key areas such as oncology and vaccines. Sales for the ...
A new cell and gene therapy initiative from ... US Food and Drug Administration (FDA) make a land-mark decision to approve the first gene therapies for sickle cell disease (SCD) – Vertex ...
Steve Smith, general manager of U.S. operations, said Solvias will occupy the first phase of the site by the end of ... While some companies have slowed investments around cell and gene therapy amid a ...
The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk ...
Previously approved as a second-line treatment in 2015, following Pfizer’s Xalkori (crizotinib) for metastatic ALK-positive ...
Good day, everyone, and welcome to the Pfizer's first quarter 2024 earnings conference call. Today's call is being recorded.
Pfizer's groundbreaking $3.5 million gene therapy for Hemophilia B just got FDA approval. Here’s what it means for patients ...
The US Food and Drug Administration (FDA) on Friday approved Padcev (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with Keytruda (pembrolizumab, a PD-1 inhibitor) for the treatment of ...
ETHealthworld.com brings latest healthcare news, views and updates. Get healthcare industry & sector news from all top sources for the Indian Health industry.